Lessons Learned in Eliciting Systematic Participant Perspectives in a Combination HIV Cure Research Trial.

IF 1.5 4区 医学 Q4 IMMUNOLOGY
Karine Dubé, Hursch Patel, Steven Meanley, Lynda Dee, Anastasia Korolkova, Fang Wan, Shadi Eskaf, Meghann Williams, Rebecca Hoh, Steven G Deeks, Michael J Peluso, Jeremy Sugarman, John A Sauceda
{"title":"Lessons Learned in Eliciting Systematic Participant Perspectives in a Combination HIV Cure Research Trial.","authors":"Karine Dubé, Hursch Patel, Steven Meanley, Lynda Dee, Anastasia Korolkova, Fang Wan, Shadi Eskaf, Meghann Williams, Rebecca Hoh, Steven G Deeks, Michael J Peluso, Jeremy Sugarman, John A Sauceda","doi":"10.1089/aid.2024.0086","DOIUrl":null,"url":null,"abstract":"<p><p>Current trials toward an HIV cure involve combination strategies aimed at achieving durable antiretroviral treatment (ART)-free viral control or HIV elimination, many relying on analytical treatment interruptions (ATIs) to evaluate efficacy. Given the physical, psychosocial, and interpersonal risks associated with ATIs, it is critical to monitor participants' experiences so that support can be provided when needed. While qualitative approaches have been used in similar settings, we designed and implemented a series of short, closed-ended participant surveys in the University of California, San Francisco-amfAR trial, a single-arm multi-intervention HIV cure-related trial with an extended ATI. Surveys were administered at relevant trial timepoints to capture participants' (<i>n</i> = 10) perspectives and experiences. These included their understanding of the trial, motivations, expectations, perceived risks, benefits, and burdens of trial participation, and their perspectives on restarting ART and partner protections. We describe these data using descriptive statistics and summarize lessons learned from implementing quantitative surveys in this complex trial. Our data indicate that all respondents understood the scientific goals and requirements of participating in the trial. Most were motivated to help advance research but many expressed anxiety about participating. During the trial, respondents had limited side effects, discomfort, and trial burnout. Those who completed surveys at ART restart reported mixed (positive and negative) feelings and challenges (e.g., missed doses) when restarting ART. Participants offered various methods for partner protection during ATIs and at ART restart. Many respondents expressed future willingness to participate in a similar HIV cure trial. While the number of respondents was small, these findings are consistent with concerns identified in guidance regarding these types of trials as well as qualitative findings from earlier studies. Moreover, we demonstrated that it is feasible to implement quantitative evaluations of participants' experiences. Such approaches should be implemented in future HIV cure trials to optimize human-centered research implementation.</p>","PeriodicalId":7544,"journal":{"name":"AIDS research and human retroviruses","volume":" ","pages":""},"PeriodicalIF":1.5000,"publicationDate":"2025-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"AIDS research and human retroviruses","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1089/aid.2024.0086","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Current trials toward an HIV cure involve combination strategies aimed at achieving durable antiretroviral treatment (ART)-free viral control or HIV elimination, many relying on analytical treatment interruptions (ATIs) to evaluate efficacy. Given the physical, psychosocial, and interpersonal risks associated with ATIs, it is critical to monitor participants' experiences so that support can be provided when needed. While qualitative approaches have been used in similar settings, we designed and implemented a series of short, closed-ended participant surveys in the University of California, San Francisco-amfAR trial, a single-arm multi-intervention HIV cure-related trial with an extended ATI. Surveys were administered at relevant trial timepoints to capture participants' (n = 10) perspectives and experiences. These included their understanding of the trial, motivations, expectations, perceived risks, benefits, and burdens of trial participation, and their perspectives on restarting ART and partner protections. We describe these data using descriptive statistics and summarize lessons learned from implementing quantitative surveys in this complex trial. Our data indicate that all respondents understood the scientific goals and requirements of participating in the trial. Most were motivated to help advance research but many expressed anxiety about participating. During the trial, respondents had limited side effects, discomfort, and trial burnout. Those who completed surveys at ART restart reported mixed (positive and negative) feelings and challenges (e.g., missed doses) when restarting ART. Participants offered various methods for partner protection during ATIs and at ART restart. Many respondents expressed future willingness to participate in a similar HIV cure trial. While the number of respondents was small, these findings are consistent with concerns identified in guidance regarding these types of trials as well as qualitative findings from earlier studies. Moreover, we demonstrated that it is feasible to implement quantitative evaluations of participants' experiences. Such approaches should be implemented in future HIV cure trials to optimize human-centered research implementation.

目前为治愈艾滋病而进行的试验涉及旨在实现持久抗逆转录病毒治疗(ART)无病毒控制或根除艾滋病的组合策略,其中许多试验依赖于分析性治疗中断(ATI)来评估疗效。考虑到与 ATI 相关的身体、社会心理和人际交往风险,监测参与者的经历至关重要,以便在需要时提供支持。我们在加州大学旧金山分校-amfAR 试验中设计并实施了一系列简短、封闭式的参与者调查,该试验是一项单臂多干预 HIV 治愈相关试验,并延长了 ATI。调查在相关试验的时间点进行,以了解参与者(10 人)的观点和经历。其中包括他们对试验的理解,参与试验的动机、期望、感知到的风险、益处和负担,以及他们对重新开始抗逆转录病毒疗法和伴侣保护的看法。我们使用描述性统计描述了这些数据,并总结了在这项复杂试验中实施定量调查的经验教训。我们的数据表明,所有受访者都了解参与试验的科学目标和要求。大多数人都有帮助推进研究的动机,但也有很多人对参与试验表示焦虑。试验期间,受访者的副作用、不适感和试验倦怠感有限。在抗逆转录病毒疗法重新开始时完成调查的受试者报告了重新开始抗逆转录病毒疗法时的不同感受(积极和消极)和挑战(如错过剂量)。参与者在 ATI 期间和抗逆转录病毒疗法重新启动时提供了各种保护伴侣的方法。许多受访者表示今后愿意参加类似的艾滋病治愈试验。虽然受访者人数不多,但这些结果与指南中对此类试验的关注点以及早期研究的定性结果是一致的。此外,我们还证明了对参与者的经历进行定量评估是可行的。在未来的艾滋病治愈试验中应采用这种方法,以优化以人为本的研究实施。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
3.10
自引率
6.70%
发文量
201
审稿时长
3-6 weeks
期刊介绍: AIDS Research and Human Retroviruses was the very first AIDS publication in the field over 30 years ago, and today it is still the critical resource advancing research in retroviruses, including AIDS. The Journal provides the broadest coverage from molecular biology to clinical studies and outcomes research, focusing on developments in prevention science, novel therapeutics, and immune-restorative approaches. Cutting-edge papers on the latest progress and research advances through clinical trials and examination of targeted antiretroviral agents lead to improvements in translational medicine for optimal treatment outcomes. AIDS Research and Human Retroviruses coverage includes: HIV cure research HIV prevention science - Vaccine research - Systemic and Topical PreP Molecular and cell biology of HIV and SIV Developments in HIV pathogenesis and comorbidities Molecular biology, immunology, and epidemiology of HTLV Pharmacology of HIV therapy Social and behavioral science Rapid publication of emerging sequence information.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信